Monogram Orthopedics
Future of Joint Reconstruction.
Overview
2016
Healthcare & Pharmaceuticals
HealthTech
B2B2C
Low
High
Summary Profit and Loss Statement
Most Recent Year | Prior Year | |
---|---|---|
Revenue |
$628,246 |
$0 |
COGS |
$458,675 |
$0 |
Tax |
$0 |
$0 |
| ||
| ||
Net Income |
$-11,814,968 |
$-9,068,006 |
Summary Balance Sheet
Most Recent Year | Prior Year | |
---|---|---|
Cash |
$5,535,710 |
$5,586,748 |
Accounts Receivable |
$0 |
$0 |
Total Assets |
$8,715,366 |
$8,115,888 |
Short-Term Debt |
$0 |
$0 |
Long-Term Debt |
$0 |
$0 |
Total Liabilities |
$0 |
$0 |
Raise History
Offering Name | Close Date | Platform | Valuation/Cap | Total Raised | Security Type | Status | Reg Type |
---|---|---|---|---|---|---|---|
Monogram Orthopedics | 03/01/2024 | Self Managed | $246,000,000 | $0 | Equity - Common | Active | RegA+ |
Monogram Orthopedics | 11/21/2022 | Dealmaker Securities | $155,000,000 | $0 | Equity - Preferred | Funded | RegCF |
Monogram Orthopaedics | 02/18/2022 | StartEngine | $89,000,000 | $23,648,853 | Equity - Preferred | Funded | RegA+ |
Monogram Orthopaedics | 01/16/2021 | StartEngine | $89,900,000 | $2,965,501 | Equity - Preferred | Funded | Test the Waters / RegA+ |
Monogram Orthopaedics | 03/31/2020 | SeedInvest | $21,250,000 | $14,588,668 | Equity - Preferred | Funded | RegA+ |
Upgrade to gain access
-
$12.42 /month
billed annually - Free portfolio tracking and KingsCrowd's quantitative ratings on all raises.
- Plan Includes:
- Everything in Free, plus
- Company specific
KingsCrowd ratings (excluding risk)
- Advanced company search ( with ratings)
- Markets page filters and historical industry data
- Get Edge Annual
Edge
-
$41.58 /month
billed annually - Full site access including KingsCrowd's qualitative analyst reports.
- Plan Includes:
- Everything in Edge, plus
- Full access to detailed Analyst Reports (e.g. Top Deal, Deal to Watch, Neutral, and Underweight)
- Search and filter based on Analyst Reports
- In-depth risk ratings for every raise
- Get Edge Pro Annual
Edge Pro
Wall Street has Morningstar, S&P, and Bloomberg
The equity crowdfunding market has KingsCrowd.
Higher precision and faster surgeries. That’s the name of the game with Monogram.
At first glance, this may seem too futuristic (and borderline impossible).
I’m here to tell you that Monogram has nearly done it. The company is conducting live surgical demonstrations of its robot for the orthopedic community and is gearing up for FDA submission.
Once the company’s robot is approved by the FDA, Monogram will launch its first-generation knee offering with generic implants. Once this has been successfully rolled out to hospitals, the company will release its second generation of implants: 3D-printed implants that closely match a patient’s anatomy and stand to disrupt this space in a major way.